$nwbo @alphavestcap While a $1 pt is well above where this one continues to trade due all the negative forces, including the on going litigation, believe it should trade much higher on favorable news. This is what Grok had to say about atmp buyouts to-date: Valuations vary widely based on stage (preclinical vs. near-approval), platform tech, and pipeline breadth—often with heavy milestone components. These are primarily for companies/platforms rather than individual assets. For the latest or specific deals, values can include CVRs (contingent value rights) tied to milestones.Major buyouts/acquisitions for CAR-T and related oncology cell/immunotherapies (ATMPs) have been driven by Big Pharma's push into cell and gene therapies, especially autologous CAR-T initially, then shifting toward allogeneic, in vivo, and manufacturing platforms.alacrita.comHere are the most notable deals to date, focused on oncology immunotherapies (primarily CAR-T):Foundational/High-Value CAR-T Acquisitions (2017–2018) Gilead Sciences acquired Kite Pharma (Yescarta/autologous CD19 CAR-T) for $11.9 billion ($180/share) in 2017. This was a landmark deal establishing commercial CAR-T http://leadership.gilead.comCelgene acquired Juno Therapeutics (lisocabtagene maraleucel/liso-cel, now Breyanzi) for $9 billion ($87/share) in 2018. BMS later acquired Celgene (~$74B in 2019, incorporating Juno assets).biopharmadive.comThese two deals totaled ~$21B and set early valuation benchmarks for the field.Recent/Platform-Focused Deals (2023–2026)The focus has shifted to in vivo CAR-T, allogeneic platforms, manufacturing improvements, and autoimmune expansions, with many deals including upfront payments milestones (total potential value shown): Gilead/Arcellx (anito-cel CAR-T for multiple myeloma): $7.8 billion (2026).biospace.com Eli Lilly/Kelonia Therapeutics (in vivo CAR-T): up to $7 billion (including $3.25B upfront, 2026).stocktitan.net AbbVie/Capstan Therapeutics (in vivo targeted LNP for CAR-T/mRNA): up to $2.1 billion (2025).biopharmadive.com Eli Lilly/Orna Therapeutics (circular RNA-LNP for in vivo CAR-T): up to $2.4 billion (recent).alacrita.com AstraZeneca/Gracell Biotechnologies (FasTCAR autologous manufacturing platform): up to $1.2 billion (closed 2024).alacrita.com BMS/Orbital Therapeutics (circular RNA for in vivo CAR-T/immunotherapies): $1.5 billion (2025).pharmaceutical-technology.com Roche/Poseida Therapeutics (allogeneic CAR-T, e.g., P-BCMA-ALLO1): up to $1.5 billion (~$1B upfront, 2024).linkedin.com AstraZeneca/EsoBiotec (in vivo CAR-T): up to $1 billion (2025).theguardian.com Gilead (Kite)/Interius BioTherapeutics (in vivo lentiviral): $350 million (2025).bioinformant.com BMS/2seventy bio (Abecma CAR-T commercialization/manufacturing): $286 million (2025).regmednet.comOther Notable Mentions Smaller or manufacturing-focused deals (e.g., Novartis acquisitions of manufacturing sites or partnerships) are often undisclosed or http://lower-value.biospace.comBluebird bio (gene therapy, with some CAR-T overlap historically) was acquired privately for a low ~$29–50 million in 2025 due to financial challenges (far below prior peak valuations).fiercepharma.comTrends: Early ex vivo CAR-T deals commanded massive premiums due to first-mover advantage and approved products. Recent activity (2024–2026) emphasizes in vivo platforms to simplify manufacturing/delivery, allogeneic approaches, and expansion beyond oncology (e.g., autoimmune). Total deal values for in vivo CAR-T platforms exceeded $6–7B in
waves.trial.medpath.com